Cardiol Therapeutics Inc. Sample Contracts

INDENTURE Made as of [l] Between CARDIOL THERAPEUTICS INC. as Issuer and as Trustee
Indenture • August 3rd, 2021 • Cardiol Therapeutics Inc. • Biological products, (no disgnostic substances) • New York

CARDIOL THERAPEUTICS INC., a corporation duly organized and existing under the laws of the Province of Ontario, having its principal office at 2265 Upper Middle Road East, Suite 602, Oakville, Ontario L6H 0G5

Sample 1Sample 2Sample 3See All (15)
AutoNDA by SimpleDocs
Cardiol Therapeutics Inc. US$50,000,000 equity distribution AGREEMENT
Equity Distribution Agreement • June 9th, 2022 • Cardiol Therapeutics Inc. • Biological products, (no disgnostic substances) • New York

Cardiol Therapeutics Inc., a corporation organized under the laws of the Province of Ontario, Canada (the “Company”), confirms its agreement (this “Agreement”) with Canaccord Genuity LLC (“Canaccord”) and Cantor Fitzgerald & Co. (“Cantor” and together with Canaccord, the “Agents” and each, an “Agent”) to issue and sell common shares of the Company (the “Common Shares”) upon and subject to the terms and conditions contained herein.

Sample 1Sample 2Sample 3
CERTAIN CONFIDENTIAL INFORMATION (MARKED BY BRACKETS AS “[***]”) HAS BEEN EXCLUDED FROM THIS EXHIBIT BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) THE REGISTRANT CUSTOMARILY AND ACTUALLY TREATS THE INFORMATION AS PRIVATE OR CONFIDENTIAL.
Stock Option Agreement • April 1st, 2024 • Cardiol Therapeutics Inc. • Biological products, (no disgnostic substances)

Further to our recent discussions, we are pleased to offer you employment at Cardiol Therapeutics Inc. (the “Corporation”) as the Chief Financial Officer, on a part-time basis on the following terms and conditions.

Sample 1Sample 2
Certain identified information has been excluded from the exhibit pursuant to Item 601(a)(6) of Regulation S-K due to personal privacy concerns. Redacted information is indicated by: [***] EXCLUSIVE SUPPLY AGREEMENT
Exclusive Supply Agreement • April 1st, 2024 • Cardiol Therapeutics Inc. • Biological products, (no disgnostic substances)

THIS EXCLUSIVE SUPPLY AGREEMENT (this “Agreement”) is made as of September 28, 2018 (the “Effective Date”), by and between Noramco, Inc., a Georgia corporation, with offices at 500 Swedes Landing Road, Wilmington, Delaware 19801, USA (“Noramco”), and Cardiol Therapeutics Inc., an Ontario corporation located at 2275 Upper Middle Road East, Suite 101, Oakville, ON, Canada, L6H 0C3 (“Buyer”). Noramco and Buyer may be referred to herein each as a “Party” or together as the “Parties”, as the context may require.

Sample 1Sample 2
CARDIOL THERAPEUTICS INC. (the “Corporation”) -and- CHRISTOPHER WADDICK (the “Employee”) (Each a “Party” and together the “Parties”)
Employment Agreement • April 1st, 2024 • Cardiol Therapeutics Inc. • Biological products, (no disgnostic substances)

WHEREAS the Employee is currently employed by the Corporation and the terms and conditions of his employment are governed by an employment agreement dated April 16, 2018, including the addendum agreement dated December 23, 2021 (the “Employment Agreement”);

Sample 1Sample 2
CARDIOL THERAPEUTICS INC. (the “Corporation”) -and- CHRISTOPHER WADDICK (the “Employee”) (Each a “Party” and together the “Parties”)
Employment Agreement • April 1st, 2024 • Cardiol Therapeutics Inc. • Biological products, (no disgnostic substances)

WHEREAS the Employee is currently employed by the Corporation and the terms and conditions of his employment are governed by an employment agreement dated April 16, 2018 (the “Employment Agreement”);

Sample 1Sample 2
CERTAIN IDENTIFIED INFORMATION HAS BEEN EXCLUDED FROM THE EXHIBIT PURSUANT TO ITEM 601(A)(6) OF REGULATION S-K DUE TO PERSONAL PRIVACY CONCERNS. REDACTED INFORMATION IS INDICATED BY: [***] EXECUTIVE EMPLOYMENT AGREEMENT
Executive Employment Agreement • April 1st, 2024 • Cardiol Therapeutics Inc. • Biological products, (no disgnostic substances)
Sample 1Sample 2
EMPLOYMENT AGREEMENT
Employment Agreement • April 1st, 2024 • Cardiol Therapeutics Inc. • Biological products, (no disgnostic substances) • New York

THIS EMPLOYMENT AGREEMENT (the “Agreement”) is entered into on May 30th 2022 by and between Cardiol Therapeutics USA Inc. (the “Company”) and Andrew Warwick Hamer (the “Executive”) (collectively, the “Parties”).

Sample 1Sample 2
CARDIOL THERAPEUTICS INC. (the “Corporation”) -and- BERNARD LIM (the “Employee”) (Each a “Party” and together the “Parties”).
Employment Agreement • April 1st, 2024 • Cardiol Therapeutics Inc. • Biological products, (no disgnostic substances)

WHEREAS the Employee is currently employed by the Corporation and the terms and conditions of his employment are governed by an employment agreement dated December 3, 2020 (the “Employment Agreement”);

Sample 1Sample 2
Certain identified information has been excluded from the exhibit pursuant to Item 601(a)(6) of Regulation S-K due to personal privacy concerns. Redacted information is indicated by: [***] DEVELOPMENT AGREEMENT
Development Agreement • April 1st, 2024 • Cardiol Therapeutics Inc. • Biological products, (no disgnostic substances)

NOW THEREFORE, in consideration of the premises and the mutual covenants and agreements set forth herein, the Parties agree as follows:

Sample 1Sample 2
Certain identified information has been excluded from the exhibit pursuant to Item 601(a)(6) of Regulation S-K due to personal privacy concerns. Redacted information is indicated by: [***] LICENSE AGREEMENT
License Agreement • April 1st, 2024 • Cardiol Therapeutics Inc. • Biological products, (no disgnostic substances) • Alberta

This License Agreement (“License Agreement”) is made this 20th day of January, 2017 (the “Effective Date”) by and between Meros Polymers Inc., a company incorporated under the laws of Alberta, with a principal place of business at 1700 Enbridge Centre, 10175 — 101 Street NW, Edmonton, Alberta T5J 0H3, Canada (“Meros”), and Cardiol Therapeutics Inc. (“Cardiol”) a company incorporated under the laws of Ontario, with a principal place of business at 2275 Upper Middle Road East, Suite 101, Oakville, Ontario, L6H 0C3 (together with any Affiliate to which this Agreement may be assigned pursuant to Section 18.8 hereof). For purposes hereof, Meros and Cardiol. are each referred to hereinafter individually as a “Party” and together as the “Parties”. For purposes hereof, capitalized terms not otherwise defined herein shall have the meanings assigned such terms in Article 1 hereof, or as otherwise indicated.

Sample 1Sample 2
PERSONAL AND CONFIDENTIAL
Cardiol Therapeutics Inc. • April 1st, 2024 • Biological products, (no disgnostic substances)

Further to our recent discussions, we are pleased to offer you employment at Cardiol Therapeutics Inc. (the “Corporation”) as Chief Operating Officer on the following terms and conditions.

Sample 1Sample 2
Certain identified information has been excluded from the exhibit pursuant to Item 601(a)(6) of Regulation S-K due to personal privacy concerns. Redacted information is indicated by: [***] EXCLUSIVE MASTER SERVICES AGREEMENT
Exclusive Master Services Agreement • April 1st, 2024 • Cardiol Therapeutics Inc. • Biological products, (no disgnostic substances)

Dalton Chemical Laboratories, Inc. o/a Dalton Pharma Services, a corporation incorporated under the laws of the Province of Ontario, Canada whose principal operations are located at: 349 Wildcat Road, Toronto, ON, M3J 253, Canada together with its subsidiaries and affiliates (as defined below), (hereinafter referred to as “CONTRACTOR”)

Sample 1Sample 2
CARDIOL THERAPEUTICS INC. (the “Corporation”) -and- DAVID ELSLEY (the “Employee”) (Each a “Party” and together the “Parties”)
Employment Agreement • April 1st, 2024 • Cardiol Therapeutics Inc. • Biological products, (no disgnostic substances)

WHEREAS the Employee is currently employed by the Corporation and the terms and conditions of his employment are governed by an employment agreement dated January 19, 2017 (the “Employment Agreement”);

Sample 1Sample 2
Cardiol Therapeutics Inc. 16,350,000 Units UNDERWRITING AGREEMENT
Underwriting Agreement • November 4th, 2021 • Cardiol Therapeutics Inc. • Biological products, (no disgnostic substances) • New York
Sample 1
INDENTURE Made as of [l] Between CARDIOL THERAPEUTICS INC. as Issuer and as Trustee
Indenture • July 5th, 2024 • Cardiol Therapeutics Inc. • Biological products, (no disgnostic substances) • New York
Sample 1
CARDIOL THERAPEUTICS INC. - and - COMPUTERSHARE TRUST COMPANY OF CANADA WARRANT INDENTURE November 5, 2021
Cardiol Therapeutics Inc. • November 5th, 2021 • Biological products, (no disgnostic substances) • Ontario

COMPUTERSHARE TRUST COMPANY OF CANADA a trust company continued under the laws of Canada and registered to carry on business in each of Provinces of Canada

Sample 1
Time is Money Join Law Insider Premium to draft better contracts faster.